International pharmaceutical group Recordati has acquired 100% stake in Italian pharmaceutical company Italchimici for €130m.
Recordati has made the acquisition from Progressio SGR, manager of the fund Progressio Investimenti II, IDeA Capital Funds SGR, manager of the fund Fondo IDeA Efficienza Energetica e Sviluppo Sostenibile, and from managers of Italchimici itself.
Recordati chairman and chief executive officer Giovanni Recordati said: “The acquisition of Italchimici represents an excellent opportunity to accelerate growth within the group, and in particular the Italian market, with an interesting portfolio of well-known products that have significant market shares.
“We are developing a growing presence within the area of gastroenterology and the consolidated Italchimici brands, much appreciated by the medical community, represent a valid complement to our current portfolio.”
The €130m transaction value will be funded by Recordati from existing liquidity.
Progressio chief executive officer Filippo Gaggini said: “Thanks to extraordinary managers such as Riccardo Zagaria (CEO), Emanuele Loiacono (Commercial Director), Barbara Mazza (Strategic Marketing Director) and Riccardo Baraldi (CFO), we have been able to complete a very interesting transaction in the pharmaceutical sector.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“Once again we have shown how important it is in the management of a fund to be able to identify, with the support of quality managers, companies with solid fundamentals and development potential.”
Headquartered in Milan, Italchimici enjoyed revenues of €46m last year.
The Italian pharmaceutical company provides therapeutical solutions, which comprise pharmaceutical products and food supplements, as well as medical devices primarily for gastroenterological and respiratory problems.